<DOC>
	<DOCNO>NCT00535418</DOCNO>
	<brief_summary>This study ass optimal duration pre-operative treatment letrozole correlate clinical efficacy appropriate surrogate marker .</brief_summary>
	<brief_title>Optimal Duration Pre-operative Treatment With Letrozole Correlate Clinical Efficacy With Appropriate Surrogate Markers</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion : 1 . Female Breast Cancer patient primary invasive breast cancer , histologically confirm core needle biopsy , whose tumor estrogen ( ER ) / progesterone ( PgR ) positive ( Clinical Stage *T2 , T3 , T4a , b , c , N0 , M0 ) 2 . Patients menopause 3 . Tumor measurable clinical examination , mammography ultrasound 4 . Adequate bone marrow , renal hepatic function 5 . A life expectancy least 6 month . Exclusion criterion : 1 . Prior treatment aromatase inhibitor antiestrogens . 2 . Uncontrolled endocrine disorder diabetes mellitus , confirm hypo hyperthyroidism , Cushing´s Syndrome , Addison´s disease ( treat untreated ) , Patients unstable angina , uncontrolled cardiac disease ( e.g . Class II IV New York Heart Association 's Functional Classification ) . 3 . Patients tumor breast , evidence inflammatory breast cancer distant metastasis 4 . Patients eligible breast conserving surgery . 5 . Concomitant anticancer treatment chemotherapy , immunotherapy/biological response modifier ( BRM 's ) , endocrine therapy ( include steroid ) , bisphosphonate therapy radiotherapy . Patients receive HRT NOT exclude , provide HRT discontinue least 2 week prior entry study . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>neoadjuvant treatment</keyword>
	<keyword>treatment duration</keyword>
	<keyword>Primary hormone receptor positive</keyword>
	<keyword>breast cancer postmenopausal woman</keyword>
</DOC>